NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE MKT: ELMD) today announced that it has formed a bronchiectasis advisory board composed of three renowned experts in pulmonary medicine. The bronchiectasis advisory board will serve as a key strategic resource to advance bronchiectasis awareness and help guide the development of clinical research plans and future airway clearance therapy innovations.
The members of the board include:
- Chad Marion, DO, PhD, is an Assistant Professor and Associate Director of the Adult Cystic Fibrosis Program of Medicine at Wake Forest Baptist Health and board-certified in Internal Medicine and Pulmonary Disease. Dr. Marion’s research interests include cystic fibrosis, non-CF bronchiectasis, opportunistic infections of the lung, bacteria, pneumonia, respiratory tract infections, gram-negative bacterial infections, and sepsis.
- Peadar Noone, MD, FCCP, FRCPI, DCH, MRCGP, is a Professor of Medicine and Medical Director for the University of North Carolina Center for Bronchiectasis Care. Dr. Noone's scholarly activities include national and international clinical expertise in cystic fibrosis, primary ciliary dyskinesia, non-CF bronchiectasis, and nontuberculous mycobacterial lung infections.
- Anne O’Donnell, MD, is the Professor of Medicine and Chief, Division of Pulmonary, Critical Care, and Sleep Medicine at Georgetown University Medical Center. Dr. O’Donnell’s special interests include bronchiectasis, respiratory infections, including nontuberculous mycobacterium, sleep apnea and sleep disorders, cystic fibrosis, and non-invasive ventilation.
“Electromed is committed to engaging clinicians, payers and patients with evidence-based information to advance bronchiectasis awareness,” commented Kathleen Skarvan, President and Chief Executive Officer of Electromed. “We are thrilled to have Dr. Noone, Dr. O’Donnell, and Dr. Marion – global thought leaders in the field of pulmonary medicine – join the Electromed bronchiectasis advisory board. In collaboration with these distinguished physicians, Electromed will continue to focus on educating the healthcare community on the effectiveness and value of airway clearance therapy in improving patients’ quality of life and reducing bronchiectasis healthcare utilization and associated costs.”
About Electromed, Inc.
Electromed manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota and founded in 1992. Further information about Electromed can be found at www.smartvest.com.